Skye Bioscience, Inc.
SKYE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18,702 | $5,819 | $6,012 | $2,931 |
| G&A Expenses | $17,726 | $7,852 | $6,095 | $4,916 |
| SG&A Expenses | $17,726 | $7,852 | $6,095 | $4,916 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$6,235 | $21,063 | $6,205 | $0 |
| Operating Expenses | $30,193 | $34,735 | $18,312 | $7,848 |
| Operating Income | -$30,193 | -$34,735 | -$18,312 | -$7,848 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,636 | -$2,906 | -$1,163 | -$672 |
| Pre-Tax Income | -$26,557 | -$37,641 | -$19,475 | -$8,520 |
| Tax Expense | $10 | $4 | $7 | $2 |
| Net Income | -$26,567 | -$37,645 | -$19,482 | -$8,522 |
| % Margin | – | – | – | – |
| EPS | -0.73 | -5.37 | -8.77 | -5 |
| % Growth | 86.4% | 38.8% | -75.4% | – |
| EPS Diluted | -0.73 | -5.37 | -8.77 | -5 |
| Weighted Avg Shares Out | 36,487 | 7,006 | 2,221 | 1,626 |
| Weighted Avg Shares Out Dil | 36,487 | 7,006 | 2,221 | 1,626 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,264 | $100 | $19 | $0 |
| Interest Expense | $968 | $906 | $664 | $768 |
| Depreciation & Amortization | $299 | $124 | $115 | $34 |
| EBITDA | -$25,291 | -$36,620 | -$18,696 | -$7,718 |
| % Margin | – | – | – | – |